Search

Your search keyword '"He, Qing-Mei"' showing total 208 results
Start Over Author "He, Qing-Mei"
208 results on '"He, Qing-Mei"'

3. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment

Author

Lv, Jiawei, Wei, Yuan, Yin, Jian-Hua, Chen, Yu-Pei, Zhou, Guan-Qun, Wei, Chen, Liang, Xiao-Yu, Zhang, Yuan, Zhang, Cui-Juan, He, Shi-Wei, He, Qing-Mei, Huang, Zhuo-Li, Guan, Jia-Li, Shen, Jia-Yi, Li, Xiao-Min, Li, Jun-Yan, Li, Wen-Fei, Tang, Ling-Long, Mao, Yan-Ping, Guo, Rui, Sun, Rui, Zheng, Yu-Hui, Zhou, Wen-Wen, Xiong, Ke-Xu, Wang, Si-Qi, Jin, Xin, Liu, Na, Li, Gui-Bo, Kuang, Dong-Ming, Sun, Ying, and Ma, Jun

Published
2023
Full Text
View/download PDF

8. Correction: Zhao et al. Hypermethylation of UCHL1 Promotes Metastasis of Nasopharyngeal Carcinoma by Suppressing Degradation of Cortactin (CTTN). Cells 2020, 9, 559

Author

Zhao, Yin, primary, Lei, Yuan, additional, He, Shi-Wei, additional, Li, Ying-Qin, additional, Wang, Ya-Qin, additional, Hong, Xiao-Hong, additional, Liang, Ye-Lin, additional, Li, Jun-Yan, additional, Chen, Yang, additional, Luo, Wei-Jie, additional, Zhang, Pan-Pan, additional, Yang, Xiao-Jing, additional, He, Qing-Mei, additional, Ma, Jun, additional, Liu, Na, additional, and Tang, Ling-Long, additional

Published
2024
Full Text
View/download PDF

12. Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses

Author

Chen, Yu-Pei, Lv, Jia-Wei, Mao, Yan-Ping, Li, Xiao-Min, Li, Jun-Yan, Wang, Ya-Qin, Xu, Cheng, Li, Ying-Qin, He, Qing-Mei, Yang, Xiao-Jing, Lei, Yuan, Shen, Jia-Yi, Tang, Ling-Long, Chen, Lei, Zhou, Guan-Qun, Li, Wen-Fei, Du, Xiao-Jing, Guo, Rui, Liu, Xu, Zhang, Yuan, Zeng, Jing, Yun, Jing-Ping, Sun, Ying, Liu, Na, and Ma, Jun

Published
2021
Full Text
View/download PDF

13. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma

Author

Chen, Yu-Pei, Yin, Jian-Hua, Li, Wen-Fei, Li, Han-Jie, Chen, Dong-Ping, Zhang, Cui-Juan, Lv, Jia-Wei, Wang, Ya-Qin, Li, Xiao-Min, Li, Jun-Yan, Zhang, Pan-Pan, Li, Ying-Qin, He, Qing-Mei, Yang, Xiao-Jing, Lei, Yuan, Tang, Ling-Long, Zhou, Guan-Qun, Mao, Yan-Ping, Wei, Chen, Xiong, Ke-Xu, Zhang, Hong-Bo, Zhu, Shi-Da, Hou, Yong, Sun, Ying, Dean, Michael, Amit, Ido, Wu, Kui, Kuang, Dong-Ming, Li, Gui-Bo, Liu, Na, and Ma, Jun

Published
2020
Full Text
View/download PDF

23. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment

Author

Lv, Jiawei, Wei, Yuan, Yin, Jian-Hua, Chen, Yu-Pei, Zhou, Guan-Qun, Wei, Chen, Liang, Xiao-Yu, Zhang, Yuan, Zhang, Cui-Juan, He, Shi-Wei, He, Qing-Mei, Huang, Zhuo-Li, Guan, Jia-Li, Shen, Jia-Yi, Li, Xiao-Min, Li, Jun-Yan, Li, Wen-Fei, Tang, Ling-Long, Mao, Yan-Ping, Guo, Rui, Sun, Rui, Zheng, Yu-Hui, Zhou, Wen-Wen, Xiong, Ke-Xu, Wang, Si-Qi, Jin, Xin, Liu, Na, Li, Gui-Bo, Kuang, Dong-Ming, Sun, Ying, and Ma, Jun

Abstract

Gemcitabine plus cisplatin (GP) chemotherapy is the standard of care for nasopharyngeal carcinoma (NPC). However, the mechanisms underpinning its clinical activity are unclear. Here, using single-cell RNA sequencing and T cell and B cell receptor sequencing of matched, treatment-naive and post-GP chemotherapy NPC samples (n= 15 pairs), we show that GP chemotherapy activated an innate-like B cell (ILB)-dominant antitumor immune response. DNA fragments induced by chemotherapy activated the STING type-I-interferon-dependent pathway to increase major histocompatibility complex class I expression in cancer cells, and simultaneously induced ILB via Toll-like receptor 9 signaling. ILB further expanded follicular helper and helper type 1 T cells via the ICOSL–ICOS axis and subsequently enhanced cytotoxic T cells in tertiary lymphoid organ-like structures after chemotherapy that were deficient for germinal centers. ILB frequency was positively associated with overall and disease-free survival in a phase 3 trial of patients with NPC receiving GP chemotherapy (NCT01872962, n= 139). It also served as a predictor for favorable outcomes in patients with NPC treated with GP and immunotherapy combined treatment (n= 380). Collectively, our study provides a high-resolution map of the tumor immune microenvironment after GP chemotherapy and uncovers a role for B cell-centered antitumor immunity. We also identify and validate ILB as a potential biomarker for GP-based treatment in NPC, which could improve patient management.

Published
2024
Full Text
View/download PDF

24. Chemotherapy‐Induced Senescence Reprogramming Promotes Nasopharyngeal Carcinoma Metastasis by circRNA‐Mediated PKR Activation

Author

Li, Qian, primary, Zhao, Yu‐Heng, additional, Xu, Cheng, additional, Liang, Ye‐Lin, additional, Zhao, Yin, additional, He, Qing‐Mei, additional, Li, Jun‐Yan, additional, Chen, Kai‐Lin, additional, Qiao, Han, additional, Liu, Na, additional, Ma, Jun, additional, Chen, Lei, additional, and Li, Ying‐Qin, additional

Published
2023
Full Text
View/download PDF

26. Association of Intratumoral Microbiota With Prognosis in Patients With Nasopharyngeal Carcinoma From 2 Hospitals in China

Author

Qiao, Han, primary, Tan, Xi-Rong, additional, Li, Hui, additional, Li, Jun-Yan, additional, Chen, Xiao-Zhong, additional, Li, Ying-Qin, additional, Li, Wen-Fei, additional, Tang, Ling-Long, additional, Zhou, Guan-Qun, additional, Zhang, Yuan, additional, Liang, Ye-Lin, additional, He, Qing-Mei, additional, Zhao, Yin, additional, Huang, Sheng-Yan, additional, Gong, Sha, additional, Li, Qian, additional, Ye, Ming-Liang, additional, Chen, Kai-Lin, additional, Sun, Ying, additional, Ma, Jun, additional, and Liu, Na, additional

Published
2022
Full Text
View/download PDF

34. Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth

Author

He, Shi‐Wei, primary, Zhang, Yuan, additional, Chen, Lei, additional, Luo, Wei‐Jie, additional, Li, Xiao‐Min, additional, Chen, Yang, additional, Huang, Sheng‐Yan, additional, He, Qing‐Mei, additional, Yang, Xiao‐Jing, additional, Li, Ying‐Qin, additional, Liu, Na, additional, Zhao, Yin, additional, and Ma, Jun, additional

Published
2021
Full Text
View/download PDF

37. Additional file 1 of Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses

Author

Chen, Yu-Pei, Lv, Jia-Wei, Mao, Yan-Ping, Li, Xiao-Min, Li, Jun-Yan, Wang, Ya-Qin, Xu, Cheng, Ying-Qin Li, He, Qing-Mei, Yang, Xiao-Jing, Lei, Yuan, Shen, Jia-Yi, Tang, Ling-Long, Chen, Lei, Zhou, Guan-Qun, Li, Wen-Fei, Du, Xiao-Jing, Guo, Rui, Liu, Xu, Zhang, Yuan, Zeng, Jing, Yun, Jing-Ping, Sun, Ying, Liu, Na, and Ma, Jun

Abstract

Additional file 1: Methods. Figure S1. Study flow. HTA, Human Transcriptome Array; ICI, immune checkpoint inhibitor; NMF, non-negative matrix factorization; NPC, nasopharyngeal carcinoma; PSM, propensity score matching. Figure S2. Identification of an NMF immune factor. (A) We applied NMF (k = 5 factors or expression patterns) to analyze the gene expression profiles of nasopharyngeal carcinoma (NPC) samples in the training cohort (n = 113). One of the five factors (green bar) showed the highest ssGSEA scores in both immune enrichment score and 6-gene IFN-γ signature, as shown in the heatmap, indicating that it is an immune factor (or an immune expression pattern). High and low ssGSEA scores are represented in red and blue, respectively. (B) The top 100 exemplar immune factor genes characterized using DAVID confirmed immune-related functions. (C) NMF consensus-clustering of the training cohort using exemplar immune factor genes was refined by random forest classification. As shown in the heatmap, an immune-enriched subtype and a non-immune subtype. The ssGSEA scores of immune enrichment score and 6-gene IFN-γ signature are indicated; high and low scores are represented in red and blue, respectively. NMF, non-negative matrix factorization; NPC, nasopharyngeal carcinoma; ssGSEA, single-sample gene set enrichment analysis. Figure S3. Association of immune subtypes with tumoural genomic features and survival outcome. (A) Box plot showing similar number of non-synonymous mutations among the immune subtypes. (B) Box plot showing similar numbers of gene-level amplifications and deletions among the immune subtypes. (C) Box plot showing significantly higher cell cycling scores in non-IS. The box plot centre corresponds to the median, with the box and whiskers corresponding to the interquartile range and 1.5× interquartile range, respectively. P-values were based on the Kruskal–Wallis rank-sum test. (D) The proportion of CDKN2A deletions was significantly higher in non-IS. P-values were based on the Fisher’s exact test. (E) Kaplan–Meier curves for progression-free survival according to immune subtypes. A trend of better survival was observed for A-IS compared to E-IS and non-IS in 88 patients with available survival outcomes. P-values were calculated by log-rank test. A-IS, active immune subtype; CD4+ Tconv, conventional CD4+ T cells; CD8+ Tcyt, cytotoxic CD8+ T cells; CD8+ Tdys, dysfunctional CD8+ T cells; CD8+ Tnaï, naïve CD8+ T cells; DCs, dendritic cells; E-IS, evaded immune subtype; NK, natural killer; non-IS, non-immune subtype. Figure S4. Genetic similarity of the immune subtypes in different groups of patients from two melanoma ICI cohorts. (A) SubMap analysis of the immune subtypes in validation cohort 1 and four groups (anti-PD-1 responsive and non-responsive, and anti-CTLA-4 responsive and non-responsive) in melanoma ICI cohort 1. (B) SubMap analysis of the immune subtypes in validation cohort 1 and four groups (CR/PR/SD > 12 months, CR/PR/SD 6–12 months, CR/PR/SD 12 months for anti-PD-1 therapy (P = 0.036). A-IS, active immune subtype; CR, complete response; E-IS, evaded immune subtype; ICI, immune checkpoint inhibitor; non-IS, non-immune subtype; PD, progressive disease; PR, partial response; SD, stable disease. Table S1. Clinical cohorts used in this study. Table S2. Publicly available gene signatures used in this study. Table S7. Clinical characteristics of patients in the validation cohort 1 and validation cohort 2 (ICI).

Published
2021
Full Text
View/download PDF

38. Prognostic Value of Pretreatment Serum Cystatin C Level in Nasopharyngeal Carcinoma Patients in the Intensity-modulated Radiotherapy Era

Author

Tan,Xi-Rong, Huang,Sheng-Yan, Gong,Sha, Chen,Yang, Yang,Xiao-Jing, He,Qing-Mei, He,Shi-Wei, Liu,Na, Li,Ying-Qing, Tan,Xi-Rong, Huang,Sheng-Yan, Gong,Sha, Chen,Yang, Yang,Xiao-Jing, He,Qing-Mei, He,Shi-Wei, Liu,Na, and Li,Ying-Qing

Abstract

Xi-Rong Tan,* Sheng-Yan Huang,* Sha Gong, Yang Chen, Xiao-Jing Yang, Qing-Mei He, Shi-Wei He, Na Liu, Ying-Qing Li State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying-Qing Li; Na LiuState Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, People’s Republic of ChinaTel/Fax +86-20-87343255; +86-20-87342370Email liyingq1@sysucc.org.cn; liun1@sysucc.org.cnPurpose: Serum cystatin C has been considered as a significant prognostic factor for various malignancies. This study aimed to evaluate the relationship between serum cystatin C level before antitumor treatment and the prognosis of nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT).Patients and Methods: A cohort of 2077 NPC patients were enrolled between April 2009 and September 2012. The Kaplan–Meier curves and log rank tests were used to determine the differences of overall survival (OS) and disease-free survival (DFS). Univariate and multivariate Cox regression analyses were used to determine independent prognostic factors.Results: Overall, 362/2077 (17.4%) patients had high serum cystatin C level, and they were older and more male (both P< 0.001), and they had higher TNM stage (all P< 0.05). Kaplan–Meier analysis revealed that patients with high serum cystatin C had worse OS (P< 0.001) and DFS (P< 0.001). Univariate and multivariate Cox regression analysis showed that high serum cystatin C level was an independent prognostic predictor of OS

Published
2021

40. Serum Calcium Levels Before Antitumour Therapy Predict Clinical Outcomes in Patients with Nasopharyngeal Carcinoma

Author

Huang,Sheng-Yan, Chen,Yang, Tan,Xi-Rong, Gong,Sha, Yang,Xiao-Jing, He,Qing-Mei, He,Shi-Wei, Liu,Na, Li,Ying-Qing, Huang,Sheng-Yan, Chen,Yang, Tan,Xi-Rong, Gong,Sha, Yang,Xiao-Jing, He,Qing-Mei, He,Shi-Wei, Liu,Na, and Li,Ying-Qing

Abstract

Sheng-Yan Huang,* Yang Chen,* Xi-Rong Tan, Sha Gong, Xiao-Jing Yang, Qing-Mei He, Shi-Wei He, Na Liu, Ying-Qing Li Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Na Liu; Ying-Qing LiSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Road East, Guangzhou 510060, People’s Republic of ChinaTel/Fax +86-20-87342370; +86-20-87343255 Email liun1@sysucc.org.cn; liyingq1@sysucc.org.cnPurpose: The prognostic value of serum calcium levels in nasopharyngeal carcinoma (NPC) remains unknown. This study aimed to evaluate the prognostic value of serum calcium levels in patients with NPC.Patients and Methods: A total of 2094 patients diagnosed with NPC between April 2009 and September 2012 were enrolled in this retrospective analysis. The median follow-up time was 96.3 months (range: 4.1– 120.0 months). Univariate and multivariable Cox proportional hazards models were used to identify significant and independent prognostic predictors of overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and relapse-free survival (RFS).Results: Overall, low serum calcium levels were detected in 1109/2094 (53.00%) patients and tended to be more frequently detected in older (P< 0.001) and female (P=0.001) patients. Patients with low serum calcium levels had poorer OS (P=0.011), DFS (P=0.012) and DMFS (P=0.004) than those with high serum calcium levels, but serum calcium levels had no significant effect on RFS (P=0.376). In univariate and multivariable analyses, low serum calcium le

Published
2020

43. Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology

Author

Wang, Ya-Qin, primary, Chen, Lei, additional, Mao, Yan-Ping, additional, Li, Ying-Qing, additional, Jiang, Wei, additional, Xu, Shuo-Yu, additional, Zhang, Yu, additional, Chen, Yu-Pei, additional, Li, Xiao-Min, additional, He, Qing-Mei, additional, He, Shi-Wei, additional, Yang, Xiao-Jing, additional, Lei, Yuan, additional, Zhao, Yin, additional, Yun, Jing-Ping, additional, Liu, Na, additional, Li, Yingqin, additional, and Ma, Jun, additional

Published
2020
Full Text
View/download PDF

45. Hypermethylation of UCHL1 Promotes Metastasis of Nasopharyngeal Carcinoma by Suppressing Degradation of Cortactin (CTTN)

Author

Zhao, Yin, primary, Lei, Yuan, additional, He, Shi-Wei, additional, Li, Ying-Qin, additional, Wang, Ya-Qin, additional, Hong, Xiao-Hong, additional, Liang, Ye-Lin, additional, Li, Jun-Yan, additional, Chen, Yang, additional, Luo, Wei-Jie, additional, Zhang, Pan-Pan, additional, Yang, Xiao-Jing, additional, He, Qing-Mei, additional, Ma, Jun, additional, Liu, Na, additional, and Tang, Ling-Long, additional

Published
2020
Full Text
View/download PDF

47. Low BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survival

Author

Cui Rui-Xue, Liu Na, He Qing-Mei, Li Wen-Fei, Huang Bi-Jun, Sun Ying, Tang Ling-Long, Chen Mo, Jiang Ning, Chen Lei, Yun Jing-Ping, Zeng Jing, Guo Ying, Wang Hui-Yun, and Ma Jun

Subjects
BRMS1, Nasopharyngeal carcinoma, Metastasis, Prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Breast cancer metastasis suppressor 1 (BRMS1) is a metastasis suppressor gene. This study aimed to investigate the impact of BRMS1 on metastasis in nasopharyngeal carcinoma (NPC) and to evaluate the prognostic significance of BRMS1 in NPC patients. Methods BRMS1 expression was examined in NPC cell lines using quantitative reverse transcription-polymerase chain reaction and Western blotting. NPC cells stably expressing BRMS1 were used to perform wound healing and invasion assays in vitro and a murine xenograft assay in vivo. Immunohistochemical staining was performed in 274 paraffin-embedded NPC specimens divided into a training set (n = 120) and a testing set (n = 154). Results BRMS1 expression was down-regulated in NPC cell lines. Overexpression of BRMS1 significantly reversed the metastatic phenotype of NPC cells in vitro and in vivo. Importantly, low BRMS1 expression was associated with poor distant metastasis-free survival (DMFS, P P Conclusions Low expression of the metastasis suppressor BRMS1 may be an independent prognostic factor for poor prognosis in NPC patients.

Published
2012
Full Text
View/download PDF

48. Nuclear overexpression of metastasis-associated protein 1 correlates significantly with poor survival in nasopharyngeal carcinoma

Author

Li Wen-Fei, Liu Na, Cui Rui-Xue, He Qing-Mei, Chen Mo, Jiang Ning, Sun Ying, Zeng Jing, Liu Li-Zhi, and Ma Jun

Subjects
Nasopharyngeal carcinoma, Biomarker, MTA1, Prognosis, Medicine
Abstract

Abstract Background Metastasis-associated protein 1 (MTA1) has been associated with poor prognosis in several malignant carcinomas. The purpose of this study was to investigate the expression and prognostic value of MTA1 in nasopharyngeal carcinoma (NPC). Methods MTA1 expression was assessed using immunohistochemistry in paraffin-embedded tumor specimens from 208 untreated NPC patients. Cox regression analysis was used to calculate the hazard ratio (HR), 95% confidence interval (CI) and identify independent prognostic factors, and recursive partitioning analysis was used to create a decision tree. Results Nuclear overexpression of MTA1 was observed in 48.6% (101/208) of the NPC tissues. Nuclear overexpression of MTA1 correlated positively with N classification (P = 0.02), clinical stage (P = 0.04), distant metastasis (P < 0.01) and death (P = 0.01). Additionally, nuclear overexpression of MTA1 correlated significantly with poorer distant metastasis-free survival (DMFS; P P < 0.01). MTA1 had prognostic significance in NPC patients with stage II disease, but not stage III or IV disease. Multivariate analysis demonstrated that nuclear overexpression of MTA1 was independently associated with poorer DMFS (HR, 2.05; 95% CI, 1.13–3.72; P = 0.02) and poorer OS (HR, 1.98; 95% CI, 1.09–3.59; P = 0.03). Using recursive partitioning analysis, the NPC patients could be classified with a low, intermediate or high risk of distant metastasis and death, on the basis of clinical stage, age and MTA1 expression. Conclusion The results of this study suggest that nuclear overexpression of MTA1 correlates significantly with poorer DMFS and poorer OS in NPC. MTA1 has potential as a novel prognostic biomarker in NPC.

Published
2012
Full Text
View/download PDF

49. Additional file 3: of TIPE3 hypermethylation correlates with worse prognosis and promotes tumor progression in nasopharyngeal carcinoma

Author

Xian-Yue Ren, Wen, Xin, Li, Ying-Qing, Zhang, Jian, He, Qing-Mei, Yang, Xiao-Jing, Tang, Xin-Ran, Wang, Ya-Qin, Pan-Pan Zhang, Chen, Xiao-Zhong, Cheng, Bin, Ma, Jun, and Liu, Na

Abstract

Table S3. Univariate Cox regression analyses of the significant of different prognostic variables in nasopharyngeal carcinoma. (DOCX 19Â kb)

Published
2018
Full Text
View/download PDF

50. Additional file 2: of Differential genome-wide profiling of alternative polyadenylation sites in nasopharyngeal carcinoma by high-throughput sequencing

Author

Xu, Ya-Fei, Li, Ying-Qing, Liu, Na, He, Qing-Mei, Tang, Xin-Ran, Wen, Xin, Yang, Xiao-Jing, Sun, Ying, Ma, Jun, and Tang, Ling-Long

Subjects
stomatognathic diseases, fungi, otorhinolaryngologic diseases
Abstract

The frequency distribution of the genes with lengthened 3â UTR (A) and shortened 3â UTR (B) in different pairs, comparing NPC and NNET. (PDF 123 kb)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results